Etienne Cyr Proulx-Saint

3530 Saint Laurent Boulevard, Suite 400
Montreal, QC H2X2V1, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.

EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.

Journal: Dermatology and therapy

Published: May 12, 2026

Gut microbiome of patients with nonatopic chronic hand eczema (CHE) is distinct and enriched in immunomodulatory bacteria species compared with patients with atopic CHE and healthy individuals.

Gut microbiome of patients with nonatopic chronic hand eczema (CHE) is distinct and enriched in immunomodulatory bacteria species compared with patients with atopic CHE and healthy individuals.

Journal: The British journal of dermatology

Published: November 06, 2025

Ruxolitinib cream demonstrated rapid reductions in itch and atopic dermatitis signs that correlated with biomarkers.

Ruxolitinib cream demonstrated rapid reductions in itch and atopic dermatitis signs that correlated with biomarkers.

Journal: The Journal of investigative dermatology

Published: June 03, 2025

Ethnicity, Race and Skin Color: Challenges and Opportunities for Atopic Dermatitis Clinical Trials.

Ethnicity, Race and Skin Color: Challenges and Opportunities for Atopic Dermatitis Clinical Trials.

Journal: Journal of clinical medicine

Published: April 26, 2023

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.

Journal: Journal of drugs in dermatology : JDD

Published: February 06, 2023

Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research.

Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 23, 2022

Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study.

Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 28, 2022

Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response.

Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response.

Journal: Allergy

Published: December 17, 2020

Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis.

Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis.

Journal: The Journal of allergy and clinical immunology

Published: March 11, 2020

Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy.

Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy.

Journal: The Journal of investigative dermatology

Published: March 15, 2019

Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.

Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.

Journal: The Journal of allergy and clinical immunology

Published: March 06, 2019

Showing 1-11 of 11

Last Updated: 09/26/2026